ArticleBiomolecules2021

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients.

Thomas Bartl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.